Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

NCT02960893

Spinocerebellar Ataxias Spinocerebellar Ataxia Genotype Type 1 Spinocerebellar Ataxia Genotype Type 2 +5 more

COMPLETED PHASE2/PHASE3

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT03701399

Spinocerebellar Ataxias Spinocerebellar Ataxia Type 1 Spinocerebellar Ataxia Type 2 +5 more

ACTIVE_NOT_RECRUITING PHASE3

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

NCT06529146

Spinocerebellar Ataxias

ACTIVE_NOT_RECRUITING

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

NCT06672445

Spinocerebellar Ataxia Type 2

RECRUITING PHASE1

Lithium Treatment for Patients With Spinocerebellar Ataxia Type I

NCT00683943

Spinocerebellar Ataxia Type I

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an Intermediate-Size Patient Population Expanded Access Protocol designed to provide treatment use of troriluzole to patients with spinocerebellar ataxia (SCA) who are considered to be eligible in the clinical judgement of the Investigator/treating physician. The population includes both troriluzole naive patients and patients participating in previous clinical trials with troriluzole (BHV4157-201 and BHV4157-206) who have a confirmed diagnosis of spinocerebellar ataxia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SCA Spinocerebellar Ataxias

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Troriluzole

BHV-4157 140mg, 200mg or 280mg once daily by mouth.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BHV-4157

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has a confirmed diagnosis of Spinocerebellar Ataxia (SCA), defined as either clinical evidence supporting diagnosis OR confirmed genotypic diagnosis.
* Adequate hepatic function.

Exclusion Criteria

* Patient is known to have acute or chronic liver disease that is clinically significant in the judgement of the Physician.
* Patient has a history of a clinically significant medical condition that would interfere with the patients ability to comply with the expanded access protocol or would place the patient at increased risk.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No